SLED Prescription Adjustment for Persistently Elevated BUN and Creatinine
Increase the SLED treatment duration toward 12 hours and/or increase the frequency of sessions to achieve adequate solute clearance, targeting a delivered Kt/V of at least 1.2-1.4 per treatment, while maintaining hemodynamic stability. 1
Treatment Duration and Frequency Optimization
Extend treatment sessions to the full 12-hour duration when BUN and creatinine remain elevated, as the mean delivered double-pool Kt/V of 1.36 per completed treatment in SLED requires adequate time to achieve target clearance 1
Consider increasing treatment frequency from every other day to daily sessions if solute control remains inadequate with standard scheduling, as SLED allows for flexible scheduling while maintaining hemodynamic stability 1
Monitor delivered versus prescribed dose closely, as interruptions for circuit clotting, procedures, or hypotension can reduce actual delivered clearance by 15-32% below prescribed targets 2
Blood and Dialysate Flow Rate Adjustments
Maintain the standard SLED approach of reduced blood flow rates (typically 200-300 mL/min) and low dialysate flow rates (typically 100-300 mL/min) to preserve hemodynamic stability, which is the primary advantage of SLED over conventional intermittent hemodialysis 1
Do not increase flow rates aggressively in pursuit of higher clearance, as this defeats the hemodynamic stability advantage and may lead to treatment intolerance and premature discontinuation 1
Clearance Target Monitoring
Aim for urea-based clearance targets extrapolated from maintenance hemodialysis (Kt/V ≥1.2 per treatment for SLED), recognizing these are borrowed metrics in the absence of AKI-specific adequacy measures 2
Perform direct dialysis quantification when possible to verify delivered dose, as prescribed clearance can overestimate actual delivered clearance by up to 25% due to filter efficiency decline and treatment interruptions 2
Common Pitfalls and Monitoring
Anticipate and prevent circuit clotting, which was the majority cause of premature SLED discontinuation in clinical experience, by optimizing anticoagulation protocols 1
Watch for electrolyte depletion, particularly hypophosphatemia and hypokalemia, which may require supplementation during extended SLED sessions (mean phosphate removal 1.5g per treatment) 1
Accept that some patients may require 20-25% higher prescribed flow rates than target doses to account for downtime and filter efficiency decline, though this remains debated among experts 2
Hemodynamic Considerations
Prioritize hemodynamic stability over aggressive clearance, as SLED's primary indication is for patients in whom conventional intermittent hemodialysis has failed or been withheld due to hemodynamic instability 1
Achieve ultrafiltration goals gradually over the extended treatment time, as SLED maintained hemodynamic stability in most treatments with a mean ultrafiltration shortfall of only 240 mL per treatment 1
Schedule treatments nocturnally when feasible to allow unrestricted daytime access for procedures and tests while maintaining adequate clearance 1